The agent could not access the target website (403 blocking) and instead reconstructed a product overview from search results and medical literature. The response is substantially complete on product mechanism and positioning but lacks pricing details and site-specific marketing claims that would require direct website access.

• ›The website itself is inaccessible (403 Forbidden); all substantive answers derive from search results pointing to third-party retailers, medical databases, and patent literature—not from talcid.de's own content.
• ›Search results [3] and [7] confirmed the official site exists but could not be fetched; the agent correctly flagged this as a blocker for pricing and positioning details.
• ›Steps [5] and [6] returned medical/comparative information about hydrotalcite antacids from PubMed, ResearchGate, and Wiley—this external literature formed the basis for the 'how it's different' section, not site-supplied positioning.
• ›The agent encountered a product-naming collision in search results (a PPI also called Talcid 20mg) but correctly reconciled it through clinical sources; this points to ambiguous discoverability rather than a site-navigation problem.
• ›Pricing section explicitly calls out the information gap; the agent located retailer URLs (arzneiprivat.de, Amazon.de) but could not retrieve prices, making the pricing answer incomplete and contingent on user follow-up.